Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B vaccines.

Andy S Yu1, Ramsey C Cheung, Emmet B Keeffe

  • 1Liver Transplant Program, Stanford University Medical Center, 750 Welch Road, Suite 210, Stanford, CA 94305, USA.

Clinics in Liver Disease
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies.

Gastro hep advances·2026
Same author

No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma Among Treatment Naïve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted Analysis.

Journal of clinical and experimental hepatology·2025
Same author

Comparison of Referral Rates and Costs Using Fibrosis-4 and Enhanced Liver Fibrosis (ELF) Testing Strategies for Initial Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population.

The journal of applied laboratory medicine·2025
Same author

Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma.

Gastroenterology research·2024
Same author

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis.

Journal of viral hepatitis·2024

Hepatitis B vaccination is highly effective in preventing hepatitis B virus (HBV) infection and its complications. While most individuals achieve seroprotection, factors like age and obesity can predict non-response to vaccines.

Area of Science:

  • Hepatology and Immunology
  • Vaccinology
  • Public Health

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge, leading to acute and chronic liver disease.
  • Immunization is the cornerstone of HBV prevention strategies, aiming to eliminate viral transmission.
  • National initiatives target universal vaccination for infants, children, adolescents, and at-risk adults.

Purpose of the Study:

  • To review the efficacy and safety of hepatitis B vaccination.
  • To identify factors influencing vaccine response and non-response.
  • To discuss strategies for individuals who do not achieve adequate seroprotection.

Main Methods:

  • Review of existing literature on hepatitis B immunization.
  • Analysis of seroprotection rates and adverse effects.

Related Experiment Videos

  • Identification of demographic and clinical predictors of vaccine non-response.

    • Main Results:

    • Hepatitis B vaccination achieves seroprotection (anti-HBs ≥ 10 mIU/mL) in over 95% of vaccinees.
    • Vaccines are generally well-tolerated with minimal adverse events.
    • Predictors of non-response include older age, male gender, obesity, smoking, and immunocompromising conditions.

    Conclusions:

    • Hepatitis B vaccination is a safe and highly effective public health intervention.
    • Understanding non-response predictors is crucial for targeted strategies.
    • Adjuvants may be considered for non-responders, though efficacy is variable.